Please provide your email address to receive an email when new articles are posted on . “The need to establish treatment efficacy in osteopenia has become more pressing, given the clinical trend to ...

For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according to a study published in the Jan. 16 issue of ...

Giving zoledronate every 18 months for 6 years reduced the risk of fragility fractures—both vertebral and nonvertebral—in older women with hip bone mineral density indicating osteopenia, a ...

Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...

Bone is one of the most frequent sites for metastasis in breast cancer patients often resulting in significant clinical morbidity and mortality. Bisphosphonates are currently the standard of care for ...

Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral ...

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...

MONTREAL, QUEBEC — Women age 65 years and older who had osteopenia and received an injection of zoledronate every 18 months for 6 years had a 37% lower rate of fractures than those who received ...

This trial compared zoledronate through a drip with ibandronate tablets. The treatment was for bone weakness and bone pain caused by breast cancer that has spread. This trial was supported by Cancer ...